Skip to main
VCEL
VCEL logo

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corp has demonstrated robust financial growth, highlighted by a 22% year-over-year increase in its burn care franchise, reaching $39.9 million in FY2024. The company has also seen significant expansion in its MACI product line, with revenue growing 21% year-over-year in the fourth quarter of FY2024, reflecting a three-year compound annual growth rate of 20.9%. Additionally, the anticipated launch of new products, alongside strategic salesforce expansion, is expected to drive continued revenue acceleration and profitability through 2025, positioning Vericel favorably in the biopharmaceutical market.

Bears say

Vericel Corp's stock outlook appears negatively impacted by several fundamental factors, including a decline in expected revenues for 2026 and a valuation multiple compression within the high-growth small and mid-cap sector. The company reported weaker-than-anticipated revenues for its products, with notable misses in both Epicel and NexoBrid sales, partly attributed to patient health issues and fewer grafts per patient. Additionally, the potential risks of recession, competitive dynamics impacting product uptake, and disruptions in the commercial launch of key products add to the uncertainty surrounding the company's financial performance.

Vericel (VCEL) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.